ATE283860T1 - Organosiliciumvebindungen mit der fähigkeit zur modulation von im zellkern lokalisierten hormonrezeptoren - Google Patents

Organosiliciumvebindungen mit der fähigkeit zur modulation von im zellkern lokalisierten hormonrezeptoren

Info

Publication number
ATE283860T1
ATE283860T1 AT00941321T AT00941321T ATE283860T1 AT E283860 T1 ATE283860 T1 AT E283860T1 AT 00941321 T AT00941321 T AT 00941321T AT 00941321 T AT00941321 T AT 00941321T AT E283860 T1 ATE283860 T1 AT E283860T1
Authority
AT
Austria
Prior art keywords
ability
hormone receptors
organosilicon compounds
cell nuclear
receptors localized
Prior art date
Application number
AT00941321T
Other languages
English (en)
Inventor
Richard L Beard
Michael Garst
Roshantha A Chandraratna
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE283860T1 publication Critical patent/ATE283860T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/0805—Compounds with Si-C or Si-Si linkages comprising only Si, C or H atoms
    • C07F7/0807—Compounds with Si-C or Si-Si linkages comprising only Si, C or H atoms comprising Si as a ring atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT00941321T 1999-06-11 2000-06-09 Organosiliciumvebindungen mit der fähigkeit zur modulation von im zellkern lokalisierten hormonrezeptoren ATE283860T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13873199P 1999-06-11 1999-06-11
PCT/US2000/015972 WO2000077011A1 (en) 1999-06-11 2000-06-09 Organosilyl compounds having nuclear hormone receptor modulating activity

Publications (1)

Publication Number Publication Date
ATE283860T1 true ATE283860T1 (de) 2004-12-15

Family

ID=22483369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941321T ATE283860T1 (de) 1999-06-11 2000-06-09 Organosiliciumvebindungen mit der fähigkeit zur modulation von im zellkern lokalisierten hormonrezeptoren

Country Status (11)

Country Link
US (1) US6452032B1 (de)
EP (1) EP1185539B1 (de)
JP (1) JP2003502337A (de)
CN (1) CN1368975A (de)
AT (1) ATE283860T1 (de)
AU (1) AU774538B2 (de)
BR (1) BR0011741A (de)
CA (1) CA2375797A1 (de)
DE (1) DE60016404T2 (de)
HK (1) HK1047752A1 (de)
WO (1) WO2000077011A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144360A1 (en) * 2001-11-19 2003-07-31 Allergan Sales, Inc. Composition and method for modulating BAR/FXR receptor activity
US7087636B2 (en) 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1465882B1 (de) * 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Heterocyclische modulatoren von nukleären rezeptoren
AU2003286245A1 (en) * 2002-11-25 2004-06-18 Amedis Pharmaceuticals Ltd. Silicon compounds to be used as ligands for retinoid receptors
US7618956B2 (en) * 2005-05-31 2009-11-17 The Gillette Company Reduction of hair growth
EP2545964A1 (de) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Neuartige FXR- (NR1H4)-Binde- und -Aktivitätsmodulationsverbindungen
WO2017091762A1 (en) 2015-11-25 2017-06-01 Io Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
CA3026563C (en) 2016-06-10 2023-11-28 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
CA3069672A1 (en) 2017-07-13 2019-01-17 Io Therapeutics, Inc. Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
CA3073953A1 (en) 2017-08-31 2019-03-07 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
KR102692309B1 (ko) 2019-01-15 2024-08-07 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
WO2020172075A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
CN115246856A (zh) * 2021-04-27 2022-10-28 上海旭成医药科技有限公司 视黄酸受体激动剂、其制备方法、中间体、药物组合物和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588715A (en) * 1984-06-04 1986-05-13 Sandoz, Inc. Heptenoic acid derivatives
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5234926A (en) 1987-03-20 1993-08-10 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5272156A (en) 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5162546A (en) 1989-09-19 1992-11-10 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5053523A (en) 1989-09-19 1991-10-01 Allergan, Inc. Ethynyl-chroman compounds
EP0577737A1 (de) 1991-03-26 1994-01-12 Allergan, Inc. Chromane und thiochromane mit heteroarylethinylsubstituenten in der 7-position mit retinoidahnlicher wirkung
US5134159A (en) 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
JP2856175B2 (ja) * 1996-10-25 1999-02-10 日本電気株式会社 液晶添加剤、液晶組成物およびそれを用いた液晶表示素子
US6465258B1 (en) 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism

Also Published As

Publication number Publication date
US6452032B1 (en) 2002-09-17
AU774538B2 (en) 2004-07-01
HK1047752A1 (zh) 2003-03-07
AU5604000A (en) 2001-01-02
CN1368975A (zh) 2002-09-11
CA2375797A1 (en) 2000-12-21
BR0011741A (pt) 2002-03-19
WO2000077011A1 (en) 2000-12-21
DE60016404D1 (de) 2005-01-05
EP1185539A1 (de) 2002-03-13
JP2003502337A (ja) 2003-01-21
EP1185539B1 (de) 2004-12-01
DE60016404T2 (de) 2005-10-27

Similar Documents

Publication Publication Date Title
DE60016404D1 (de) Organosiliciumvebindungen mit der fähigkeit zur modulation von im zellkern lokalisierten hormonrezeptoren
DE69911470D1 (de) In situ hergestellter batterieseparator
AU5513798A (en) Display system with modulation of an electrode voltage to alter state of the electro-optic layer
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
AU1116400A (en) A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
ATE502320T1 (de) Elektrophoretisches medium versehen mit abstandselementen
ATE349028T1 (de) Elektrooptische anzeige und kleberzusammensetzung
DK1210411T3 (da) Sammensætninger og fremgangsmåder til forbedret celledyrkning
DE69830970D1 (de) Ausgleich von Nichlinearitäten in quadraturmodulationbenutzenden Sendern
GB9706654D0 (en) Disassociation of interacting molecules
BR0016520A (pt) Processo para a redução eletroquìmica de corantes reduzìveis
ES2172899T3 (es) Soporte de aplicacion basada en dos para un modem sin controlador.
DE69423748D1 (de) Schaltung mit getakteten Kapazitäten mit niedriger Versorgungsspannung unter Verwendung von getakteten Operationsverstärkern mit optimiertem Spannungshub
WO2000070690A3 (en) Organic light emitting devices
DE69215133D1 (de) Lithium Akkumulator mir flüssigem organischem Elektrolyt
IL200132A0 (en) Method for cell adhesion and wound healing
DE60141483D1 (de) Breitband-elektrooptische modulatoren
ATE296107T1 (de) Modulatoren von regulationsproteinen
WO2005060722A3 (en) Modulation of immune system function by modulation of polypeptide arginine methyltransferases
ATE342321T1 (de) Photochrome flüssigkristallverbindungen
PT995146E (pt) Dispositivo electrocromico
EA200000961A1 (ru) Модуляторы функций рецепторов семейства рецепторов tnf/ngf и других белков
ATE85861T1 (de) Niederleistungsadressenpuffer mit aktiver wirkung.
ATE347159T1 (de) Reduzierung der vorspannung bei räumlichen lichtmodulatoren
ES2145845T3 (es) Procedimiento para el cultivo de hepatocitos bipolares adheridos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties